At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 128 enrolled
Drug / intervention
Icotinibdrug
Likely dose
Icotinib 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation
In Brief
A Phase 2 clinical trial evaluating Icotinib for Lung Neoplasms and 6 related conditions. Completed, enrolled 128 participants across 1 site.
Detailed Summary
This phase II trial studies how well icotinib works in treating patients with completely resected stage IB NSCLC harboring EGFR mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Neoplasms, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Bronchial Neoplasms, Stage IB Non-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJan 2015
Primary CompletionDec 2020
Study CompletionJul 2022
TodayJul 2026
First PostedOct 15, 2014
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2020
Study CompletionJul 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 11.7 years ago
Interventions
Icotinibdrug
Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.